Navigation Links
ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
Date:1/26/2011

MOUNTAIN VIEW, Calif., Jan. 26, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX832, an orally-administered small molecule that is a potent and selective inhibitor of the chemoattractant receptor, ChemR23.  This receptor is known to regulate inflammatory cells in disease such as psoriasis. CCX832 is the fourth and final drug candidate discovered and developed by ChemoCentryx under the Company's alliance with GlaxoSmithKline (GSK) to identify molecules targeting four specific chemokine and chemoattractant receptors.  The initiation of this Phase I clinical trial triggered a $10 million milestone payment from GSK.

"With the successful conclusion of the discovery phase of our GSK alliance, we are intensifying and expanding our efforts in our other ongoing programs that are entirely outside the GSK alliance," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "These programs include a novel drug targeting the chemokine receptor CCR2, which has just successfully completed a Phase 2 clinical trial and a cancer program targeting the receptor CXCR7, which was discovered by ChemoCentryx scientists. In addition, we are advancing programs in liver and kidney disease and in the next generation of medicines for inflammatory bowel disease, all of which offer vast opportunities in largely unmet medical needs."

About ChemR23/CCX832

The ligand for ChemR23, chemerin, is a widely expressed protein that circulates in human plasma in an inactive state and becomes biologically activated in inflammatory settings. There is building evidence that suggests chemerin may serve as a biological alarm signal that, under conditions of tissue injury, recruits ChemR23-expressing immune cells. Diseases such as psoriasis are also associated with elevated levels of activated chemerin. In preclinical studies, CCX832 has demonstrated the ability to successfully block
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
3. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
4. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
5. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
6. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
9. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
10. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
11. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... , Isis Pharmaceuticals, Third Quarter 2014 Financial Results and ... 11:30 a.m. ET / 8:30 a.m. PTWhere: , ... Simply log onto our website listed above. If you ... replay of the webcast will be available for a ...
(Date:10/30/2014)... MAHWAH, N.J. , Oct. 30, 2014 ... PGA TOUR and Champions Tour, is rounding out its ... Cup Championship in Scottsdale, AZ. ... PGA TOUR and Champions Tour that the brand has ... destination designed to educate golf fans on the importance ...
(Date:10/30/2014)... , Oct. 30, 2014  Electronic health records ... a result of government initiatives and the considerable ... providers have invested over the past five years. ... health IT, and U.S. clinicians use them on ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4
(Date:10/31/2014)... Becker's Hospital Review has published ... and Health Systems With Great Heart Programs." , ... nation in cardiovascular and thoracic healthcare. Many have ... have received recognition from reputable sources for top-of-the-line ... Becker's Hospital Review has compiled this list and ...
(Date:10/31/2014)... October 31, 2014 TheHardwareCity.com is the ... winter. Many quality electric space heaters are available at ... superior Broan-Nutone Big Heat 1500w portable electric space heater. ... available at TheHardwareCity.com, offers an energy efficient way to ... The ceramic heating elements produce 1500 Watts, ensuring a ...
(Date:10/31/2014)... PA (PRWEB) October 31, 2014 Fundraising support ... are greater gains than losses. At noon on Monday, November ... Memorial Hospital (SSMH), greater than 20 Susquehanna Health (SH) ... locks to raise awareness and funds for the new Cancer ... shave participants’ heads for this act of love and support ...
(Date:10/31/2014)... central to life. The last stage, when two daughter ... the dawn of cell biology in the Victorian era. ... to study this final step, when the dividing cell ... name given to this process by those early biologists, ... of a highly active and organized series of events. ...
(Date:10/31/2014)... October 31, 2014 Springboard Biodiesel, ... its small scale BioPro™ biodiesel processors, announced on ... further improve the performance and efficiency of small-scale ... GL95/MC12/BD380 trio will recover more than 99% ... with the glycerin by-product produced while making biodiesel. ...
Breaking Medicine News(10 mins):Health News:Becker's Hospital Review Names 100 Hospitals, Health Systems With Great Heart Programs 2Health News:Becker's Hospital Review Names 100 Hospitals, Health Systems With Great Heart Programs 3Health News:Becker's Hospital Review Names 100 Hospitals, Health Systems With Great Heart Programs 4Health News:Big Heat 1500w Electric Space Heater Now Available at TheHardwareCity.com 2Health News:Susquehanna Health Soldiers + Sailors Memorial Hospital Razing Heads to Fight Cancer 2Health News:Cell division, minus the cells 2Health News:Cell division, minus the cells 3Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3
... Jan. 30 Crowell & Moring LLP is,pleased to ... its New,York office as a member of the firm,s ... LLP, where she helped found and co-chair,the firm,s Healthcare ... the Federal Trade Commission (FTC), where she investigated and,prosecuted ...
... TSTF ), a national provider of healthcare and ... Nursing Innovations,Per Diem business unit located in Memphis, Tennessee ... all cash and a sale of,substantially all the business ... 31, 2008. Other terms of the transaction were not,disclosed., ...
... CITY, Calif. and FORT LAUDERDALE, Fla., Jan. 30, ... that,its innovative C-Port(R) Distal Anastomosis Systems will be ... the 2008 STS University. In,addition to the C-Port ... shown. These courses will be held today during ...
... especially those with genetic variant, study says , , ... secondhand smoke worsens lung function in people with ... variations, say U.S. researchers. , "Despite public health ... stating that there is no risk-free level of ...
... 30 AMICAS, Inc. (Nasdaq: AMCS ),a leader in radiology ... AMICAS are scheduled to,address investors at the UBS Global Healthcare Services ... WHEN: -- Tuesday, ... Presentation begins promptly at 11:30 a.m. (Eastern Time), ...
... Surveyed Neurologists Identify a Six-Hour Treatment Window ... New Report from Decision Resources, WALTHAM, ... of the,world,s leading research and advisory firms ... are still hopeful about,Paion/Lundbeck,s desmoteplase despite recent ...
Cached Medicine News:Health News:Former FTC Attorney Christine White Joins Crowell & Moring's Health Care and Antitrust Groups 2Health News:Former FTC Attorney Christine White Joins Crowell & Moring's Health Care and Antitrust Groups 3Health News:TeamStaff Sells Per Diem Business Unit 2Health News:TeamStaff Sells Per Diem Business Unit 3Health News:Cardica's C-Port Anastomosis Systems for Coronary Artery Bypass Graft Procedures to be Used to Train Cardiothoracic Surgeons at Society of Thoracic Surgeons (STS) University 2Health News:Cardica's C-Port Anastomosis Systems for Coronary Artery Bypass Graft Procedures to be Used to Train Cardiothoracic Surgeons at Society of Thoracic Surgeons (STS) University 3Health News:Secondhand Smoke Worsens Lung Function in Cystic Fibrosis Patients 2Health News:AMICAS to Present at UBS Global Healthcare Services Conference 2Health News:Physicians Still Hopeful About Desmoteplase for the Treatment of Acute Ischemic Stroke Despite Negative Results 2
Cordis DUCOR Catheters are available in a broad variety of French sizes and configurations. These catheters combine an atraumatic tip with either a braided or non-braided body....
The advanced center-of-the-arc system allows an infinite choice of trajectories. The system's lightweight durable frame provides accuracy, simplicity, patient mobility and accessibility....
The CRW system epitomizes simplicity, quality assurance, and versatility....
Used for complex diagnostic and interventional procedures....
Medicine Products: